Explore the Potential with AI-Driven Innovation
The focused library is created on demand with the latest virtual screening and parameter assessment technology, supported by the Receptor.AI drug discovery platform. This method is more effective than traditional methods and results in higher-quality compounds with better activity, selectivity, and safety.
Our selection of compounds is from a large virtual library of over 60 billion molecules. The production and distribution of these compounds are managed by our partner Reaxense.
In the library, a selection of top modulators is provided, each marked with 38 ADME-Tox and 32 parameters related to physicochemical properties and drug-likeness. Also, every compound comes with its best docking poses, affinity scores, and activity scores, providing a comprehensive overview.
We utilise our cutting-edge, exclusive workflow to develop focused libraries.
Fig. 1. The sreening workflow of Receptor.AI
Utilising molecular simulations, our approach thoroughly examines a wide array of proteins, tracking their conformational changes individually and within complexes. Ensemble virtual screening enables us to address conformational flexibility, revealing essential binding sites at functional regions and allosteric locations. Our rigorous analysis guarantees that no potential mechanism of action is overlooked, aiming to uncover new therapeutic targets and lead compounds across diverse biological functions.
Several key aspects differentiate our library:
partner
Reaxense
upacc
Q00LT1
UPID:
PRCD_HUMAN
Alternative names:
Progressive rod-cone degeneration protein
Alternative UPACC:
Q00LT1; B9EJD4
Background:
The Photoreceptor disk component PRCD, also known as the Progressive rod-cone degeneration protein, plays a crucial role in vision. This protein is essential for the proper functioning of photoreceptors in the retina, which are critical for converting light into visual signals.
Therapeutic significance:
Retinitis pigmentosa 36, a form of retinal dystrophy, is directly linked to mutations in the PRCD gene. Understanding the role of Photoreceptor disk component PRCD could open doors to potential therapeutic strategies aimed at restoring vision or slowing the progression of this debilitating disease.